Karyopharm Therapeutics (KPTI) Peer Comparison

$1.21

$-0.42 (-25.62%)

As on 29-Sep-2026 16:22EDT

Market cap

$37 Mln

Revenue (TTM)

$147 Mln

P/E Ratio

--

P/B Ratio

12

Div. Yield

0 %

Edit

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	37	17,274	14,841	14,411	12,927
Revenue ($ Mln)	147	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-224.74	491.50	755.85	860.62	413.60
Net Margin (%)	-153.28	17.67	71.69	35.33	24.86
RoE (%)	--	110.09	--	42.98	430.03
Price to Earnings	--	36.40	17.63	18.29	33.40
Price-To-Book	12.05	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	146.62	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	6.04	1,982.07	103.47	85.67	363.07
Gross Profit	140.12	760.62	588.53	2,236.43	1,091.18
Operating Expenses	222.93	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-82.35	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-224.77	598.92	101.11	1,035.47	583.34
Provision for Tax	-0.03	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-224.74	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-330.17	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	307.25	187.89	384.48	288.55	2,089.43
Current Liabilities	134.23	1,435.43	464.70	361.93	344.44
Total Liabilities	108.42	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	4.94	1,006.90	895.24	1,243.41	1,644.38
Current Assets	106.38	1,050.29	1,389.84	1,250.82	933.02
Total Assets	108.42	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	215.89	120.10	449.89	165.93	2,146.65
Net Current Assets	-27.86	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-75.37	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	43.38	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	30.05	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	771.62	53.56	-30.01	32.82	15.61
ROE (%)	81.86	110.09	163.18	42.98	430.03
ROA (%)	-99.96	15.64	31.68	29.32	16.19
EBIT Margin (%)	-120.04	21.13	5.73	31.04	36.28
Net Margin (%)	-153.28	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	6.81	24.67	114.85	9.23	41.15
EBIT Growth (%)	-123.46	18.70	136.39	-3.99	-14.99
Net Profit Growth (%)	-81.88	17.50	378.76	42.89	-25.78
EPS Growth (%)	13.37	26.84	353.27	50.42	-23.48
Book Value Growth (%)	58.84	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-0.68	36.06	-59.76	15.79	24.99
Price / Book Value	-0.46	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.03	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	-0.63	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.00	0.00	0.05	0.00	1.46
Current Ratio	0.79	0.73	2.99	3.46	2.71
Quick Ratio	0.76	0.73	2.32	3.38	2.31
Interest Coverage	-3.56	--	1.62	--	29.73

Operating Efficiency Ratios

	Karyopharm Therapeutics (KPTI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	20.37	15.88	21.25	13.74	27.40
Asset Turnover	0.65	0.89	0.44	0.83	0.65
Receivable days	71.20	50.42	85.52	43.48	98.04
Inventory Days	269.44	--	1,056.70	96.17	190.34
Payable days	279.66	6.26	331.01	147.97	18.62
Cash Conversion Cycle	60.97	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly